A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection

Inclusion Criteria * Signed informed consent * Age of 18 to 75 years, inclusive * HBsAg positive for ≥24 weeks prior to screening * Liver fibrosis, confirmed by biopsy and histology * Willing to use contraception Exclusion Criteria: * Female subjects who are pregnant or nursing * Prior antiviral therapy, with the exception of interferon therapy \>6 months prior to Day 1 * Severe heart failure * Present hepatocellular carcinoma and history of other cancers * Severe anemia * Advanced kidney disease * Immunosuppressive therapy within 24 weeks prior to screening * Alcohol or drug abuse within the 12 months prior to screening * Trauma or surgical procedures requiring hospitalization within 8 weeks prior to Day 1 * Planned elective surgery during the study including 9 weeks following the final dose of study drug * History of allergy against nucleoside analogs or human, humanized, chimeric, or murine monoclonal antibodies * Inability to cooperate with study personnel or a history of noncompliance to the medical regimen (i.e., subjects who would be expected to comply poorly with the treatment) * Clinically significant medical or psychiatric condition considered a high risk for participation in an investigational study * Morbid obesity (body mass index \[BMI\] \>40) * Inadequate IV access